MCID: THY028
MIFTS: 63

Thyroid Cancer malady

Cancer diseases, Endocrine diseases categories

Aliases & Classifications for Thyroid Cancer

About this section

Aliases & Descriptions for Thyroid Cancer:

Name: Thyroid Cancer 8 10 44 32
Thyroid Carcinoma 8 44 61
Thyroid Neoplasm 8 61
Malignant Neoplasm of Thyroid Gland 8
Malignant Tumour of Thyroid Gland 8
 
Head and Neck Cancer, Thyroid 8
Malignant Neoplasm of Thyroid 61
Neoplasm of Thyroid Gland 8
Thyroid Gland Neoplasm 8


Classifications:



External Ids:

Disease Ontology8 DOID:1781, DOID:3963
NCIt39 C7510, C4815
ICD9CM27 193
MeSH33 D013964
ICD1025 C73

Summaries for Thyroid Cancer

About this section
MedlinePlus:32 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. it makes hormones that help the body work normally. there are several types of cancer of the thyroid gland. you are at greater risk if you are between ages 25 and 65 are a woman are asian have a family member who has had thyroid disease have had radiation treatments to your head or neck you should see a doctor if you have a lump or swelling in your neck. doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose thyroid cancer. treatment depends on the type of cancer you have and how far the cancer has spread. many patients receive a combination of treatments. they may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Thyroid Cancer, also known as thyroid carcinoma, is related to thyroiditis and thyroid carcinoma, follicular. An important gene associated with Thyroid Cancer is NKX2-1 (NK2 homeobox 1), and among its related pathways are EGFR Transactivation by Gastrin and SHC1 events in ERBB2 signaling. The drugs interferon alfa-2b and thyroglobulin and the compounds panitumumab and phenylacetate have been mentioned in the context of this disorder. Affiliated tissues include the thryoid gl, thyroid and testes, and related mouse phenotypes are muscle and adipose tissue.

Disease Ontology:8 An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.

Wikipedia:64 Thyroid cancer is a cancer originating from follicular or parafollicular thyroid cells. more...

Related Diseases for Thyroid Cancer

About this section

Diseases related to Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 312)
idRelated DiseaseScoreTop Affiliating Genes
1thyroiditis32.8TG, TSHR, CALCA
2thyroid carcinoma, follicular31.3PTEN, NRAS, HRAS
3struma ovarii31.3TG, TSHR, NKX2-1
4multiple endocrine neoplasia31.2TG, RET, CALCA
5multinodular goiter31.2CALCA, TSHR, TG
6endemic goiter31.1TG, TSHR
7graves' disease31.1TG, PAX8, TSHR, NKX2-1
8hypothyroidism31.0NKX2-1, TSHR, TG
9goiter31.0TG, BRAF, PAX8, TSHR, RET, CALCA
10thyrotoxicosis31.0TG, TSHR
11autoimmune thyroiditis31.0TG, CALCA
12medullary thyroid carcinoma, familial31.0RET, CALCA
13paraganglioma30.8TG, RET, CALCA
14subacute thyroiditis30.8TG, TSHR
15nodular goiter30.8TG, BRAF, TSHR, RET, CALCA, HRAS
16pituitary adenoma30.6RET, PTTG1, PPARG
17neuroma30.6RET, CALCA
18nontoxic goiter30.5TG, TSHR
19retinoblastoma30.5PPARG, PIK3CA, RASSF1, CDKN1A, EGF, HRAS
20myxedema30.5TSHR, TG
21hashimoto thyroiditis30.5TG, BRAF, TSHR, RET, CALCA
22cowden disease30.5RET, PTEN, PIK3CA
23neuroendocrine tumor30.4PAX8, RET, CALCA, NKX2-1, RASSF1
24islet cell tumor30.4RET, CALCA
25leukemia30.3PIK3CA, PTTG1, TSHR, NRAS, CDKN1A, EGF
26glioblastoma multiforme30.3PIK3CA, PTEN, CDKN1A, EGF
27adenomatous polyposis coli30.3PPARG, BRAF, NRAS, RASSF1
28brain cancer30.2PIK3CA, PTEN, CDKN1A, EGF
29melanoma30.2PIK3CA, PTEN, BRAF, TSHR, NKX2-1, NRAS
30adenocarcinoma30.1PIK3CA, PTTG1, PTEN, BRAF, NKX2-1, RASSF1
31breast cancer30.0PIK3CA, PTTG1, PTEN, NKX2-1, RASSF1, CDKN1A
32papillary carcinoma30.0PAX8, TSHR, RET, CALCA, NKX2-1, HRAS
33thyroid adenoma30.0PPARG, PIK3CA, PTEN, TG, BRAF, TSHR
34glioblastoma29.9PPARG, PIK3CA, PTEN, RASSF1, CDKN1A, EGF
35astrocytoma29.8PIK3CA, PTTG1, PTEN, RASSF1, CDKN1A, EGF
36hepatocellular carcinoma29.6PIK3CA, PTTG1, PTEN, NKX2-1, RASSF1, KISS1R
37thyroid carcinoma, papillary29.5EGF, CDKN1A, KISS1R, NNMT, PPARG, PIK3CA
38thyroid cancer, anaplastic29.5PAX8, TSHR, RET, CALCA, NKX2-1, CDKN1A
39adenoma29.5PPARG, PTTG1, TG, BRAF, PAX8, TSHR
40follicular adenoma29.4PPARG, PTEN, TG, BRAF, PAX8, TSHR
41cervicitis10.6
42leopard syndrome10.6HRAS
43endotheliitis10.5
44cowden syndrome 110.5PTEN
45thyroid carcinoma, hurthle cell10.5
46familial papillary thyroid carcinoma10.5
47toxic diffuse goiter10.5TSHR, TG
48cardiofaciocutaneous syndrome10.4BRAF
49hyperthyroidism10.4
50spitz nevus10.4BRAF, HRAS

Graphical network of the top 20 diseases related to Thyroid Cancer:



Diseases related to thyroid cancer

Symptoms for Thyroid Cancer

About this section

Drugs & Therapeutics for Thyroid Cancer

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Cometriq13 38 CABOZANTINIB S-MALATE Exelixis Approved November 2012
FDA Label: Cometriq
Malady that Drug Treats: thyroid cancer
Indications and Usage:13 COMETRIQ is a kinase inhibitor indicated for the treatment of; patients with progressive, metastatic medullary thyroid cancer; (MTC). (1)
DrugBank Targets:11 1. Hepatocyte growth factor receptor; 2. Vascular endothelial growth factor receptor 2; 3. Proto-oncogene tyrosine-protein kinase receptor Ret
Mechanism of Action:13 
Target: tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2
Action: inhibitor
FDA: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine; kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2.; These receptor tyrosine kinases are involved in both normal cellular function and pathologic; processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor; microenvironment. ;
2
Lenvima13 38 LENVATINIB MESYLATE Eisai Approved February 2015
FDA Label: Lenvima
Malady that Drug Treats: thyroid cancer
Indications and Usage:13 LENVIMA is a kinase inhibitor indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (1).
DrugBank Targets:11 1. Vascular endothelial growth factor receptor 1; 2. Vascular endothelial growth factor receptor 2; 3. Vascular endothelial growth factor receptor 3; 4. Fibroblast growth factor receptor 1; 5. Fibroblast growth factor receptor 2; 6. Fibroblast growth factor receptor 3; 7. Fibroblast growth factor receptor 4; 8. Platelet derived growth factor receptor alpha; 9. RET; 10. Mast/stem cell growth factor receptor Kit
Mechanism of Action:13 
Target: kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
Action: inhibitor
FDA: Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of; vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR),; and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in; pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal; cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the; platelet derived growth factor receptor alpha (PDGFR±), KIT, and RET.
3
Nexavar13 38 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005
FDA Label: Nexavar
Malady that Drug Treats: Renal Cell Carcinoma
Indications and Usage:13 NEXAVAR is a kinase inhibitor indicated for the treatment of ; Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12); Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:11 1. Serine/threonine-protein kinase B-raf; 2. RAF proto-oncogene serine/threonine-protein kinase; 3. Vascular endothelial growth factor receptor 3; 4. Vascular endothelial growth factor receptor 2; 5. Receptor-type tyrosine-protein kinase FLT3; 6. Platelet-derived growth factor receptor beta; 7. Mast/stem cell growth factor receptor Kit; 8. Fibroblast growth factor receptor 1; 9. Proto-oncogene tyrosine-protein kinase receptor Ret; 10. Vascular endothelial growth factor receptor 1
Mechanism of Action:13 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.; Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface; kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these; kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor; growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor; angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis; wer e obser ved in models of HCC, RCC, and DTC.
4
Vandetanib13 38 vandetanib AstraZeneca Approved April 2011
FDA Label: -
Malady that Drug Treats: thyroid cancer
Indications and Usage:13 -
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Epidermal growth factor receptor; 3. Protein-tyrosine kinase 6; 4. Angiopoietin-1 receptor
Mechanism of Action:13 
Target: tyrosine kinases
Action: inhibitor
FDA: -

Drug clinical trials:

Search ClinicalTrials for Thyroid Cancer

Search NIH Clinical Center for Thyroid Cancer

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Thyroid Cancer

About this section

Anatomical Context for Thyroid Cancer

About this section

MalaCards organs/tissues related to Thyroid Cancer:

31
Thyroid, Testes, Lymph node, Endothelial, Bone, Lung, Pituitary, Breast, T cells, Liver, Salivary gland, Skin, Ovary, Myeloid, Thymus, Brain, Colon, Prostate, Testis, Cervix, Nk cells

FMA organs/tissues related to Thyroid Cancer:

14
The thryoid gl

Animal Models for Thyroid Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Thyroid Cancer:

35 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053699.1PIK3CA, BRAF, PPARG, CDKN1A, RET, PTEN
2MP:00053759.1PIK3CA, BRAF, PTTG1, PPARG, PTEN, CDKN1A
3MP:00053889.0CALCA, RET, PTEN, HRAS, NKX2-1, BRAF
4MP:00053708.9KISS1R, CDKN1A, BRAF, PTEN, NRAS, PPARG
5MP:00053918.9CDKN1A, NRAS, EGF, PTEN, BRAF, PIK3CA
6MP:00053818.9PTEN, KISS1R, BRAF, RET, NKX2-1, NRAS
7MP:00053778.9CALCA, PPARG, PAX8, TSHR, CDKN1A
8MP:00053908.7CDKN1A, PPARG, PTEN, BRAF, PAX8, CALCA
9MP:00030128.7PPARG, PIK3CA, RET, PTTG1, NKX2-1, PAX8
10MP:00107718.5NRAS, CALCA, PTEN, PPARG, BRAF, KISS1R
11MP:00020068.4RET, CDKN1A, RASSF1, CALCA, PPARG, PIK3CA
12MP:00028738.4EGF, HRAS, KISS1R, RASSF1, NRAS, CALCA
13MP:00053978.3PPARG, BRAF, PTTG1, PTEN, TG, TSHR
14MP:00053808.2PPARG, CALCA, RET, BRAF, PTEN, PTTG1
15MP:00053678.2CDKN1A, HRAS, CALCA, KISS1R, BRAF, PPARG
16MP:00053858.1RET, PPARG, PIK3CA, PTEN, BRAF, PAX8
17MP:00053848.1NKX2-1, PAX8, BRAF, PTEN, PTTG1, PIK3CA
18MP:00053868.0RET, NKX2-1, KISS1R, CDKN1A, TSHR, BRAF
19MP:00053877.9PIK3CA, RET, TSHR, BRAF, PTEN, PTTG1
20MP:00053897.9PAX8, BRAF, PTEN, PTTG1, PIK3CA, TSHR
21MP:00053797.6TG, BRAF, TSHR, PTEN, PIK3CA, PPARG
22MP:00036317.5HRAS, CDKN1A, KISS1R, NKX2-1, CALCA, RET
23MP:00053787.4PPARG, NKX2-1, PIK3CA, PTTG1, PTEN, TG
24MP:00107687.2TSHR, PAX8, BRAF, CDKN1A, CALCA, NKX2-1
25MP:00053767.1RASSF1, KISS1R, CDKN1A, PIK3CA, HRAS, TSHR

Publications for Thyroid Cancer

About this section

Articles related to Thyroid Cancer:

(show top 50)    (show all 1661)
idTitleAuthorsYear
1
Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations. (25855579)
2015
2
Association of the miR-149 Rs2292832 Polymorphism with Papillary Thyroid Cancer Risk and Clinicopathologic Characteristics in a Chinese Population. (25405731)
2014
3
Commentary on: Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. (23987661)
2013
4
Evolving approaches to patients with advanced differentiated thyroid cancer. (23575762)
2013
5
Synoptic pathology reporting for thyroid cancer: a review and institutional experience. (24053206)
2013
6
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. (23640345)
2013
7
High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal. (24040896)
2013
8
Differentiated thyroid cancer: indications and extent of central neck dissection--our experience. (24282633)
2013
9
Severe Hyponatremia Following Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer. (24093878)
2013
10
Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. (23775351)
2013
11
The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. (24045534)
2013
12
MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition. (23900743)
2013
13
Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer. (23652675)
2013
14
Marginal treatment benefit in anaplastic thyroid cancer. (23839797)
2013
15
Accidental discovery of lung metastases from differentiated thyroid cancer by 99mTc sodium pertechnetate scan in a patient with secondary hyperparathyroidism. (22889782)
2012
16
Incidental detection of hyperfunctioning thyroid cancer metastases in patients presenting with thyrotoxicosis. (22837931)
2012
17
BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. (22426956)
2012
18
Extended RET gene analysis in patients with apparently sporadic medullary thyroid cancer: clinical benefits and cost. (22648435)
2012
19
Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer. (21826673)
2012
20
Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. (23050789)
2012
21
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. (21606412)
2011
22
Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. (21803186)
2011
23
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. (22105174)
2011
24
Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation? (21711375)
2011
25
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. (20371662)
2010
26
Thyroid cancers amongst goiter population in a Nigerian tertiary hospital: surgical and radiographic perspective. (21526634)
2010
27
The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice]. (19627734)
2009
28
Follicular thyroid cancer cell growth inhibition by proteosome inhibitor MG132. (19552924)
2009
29
Medullary thyroid cancer: molecular biology and novel molecular therapies. (19468197)
2009
30
Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence. (19769825)
2009
31
Genetic aspects of familial thyroid cancer. (19465682)
2009
32
The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. (18166820)
2008
33
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. (17538522)
2008
34
Dysregulated RET signaling in thyroid cancer. (18502331)
2008
35
Predicting the development of Cushing's syndrome in medullary thyroid cancer: utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization. (17696832)
2007
36
Normocalcemic, subclinical, asymptomatic primary hyperparathyroidism in patients with goiter or papillary thyroid cancer--preliminary report. Normocalcemic primary hyperparathyroidism and thyroid pathology. (17966885)
2007
37
Positive predictive value of detectable stimulated tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months. (17123341)
2006
38
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. (16263812)
2006
39
Risk of thyroid cancer after childhood exposure to ionizing radiation for tinea capitis. (17018661)
2006
40
Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms. (15767343)
2005
41
Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer. (16189643)
2005
42
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. (15743786)
2005
43
Papillary thyroid cancer with chest metastases only detected using radioactive iodine. (15605906)
2004
44
Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. (15232654)
2004
45
Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)]. (15316577)
2004
46
Pulmonary epithelioid hemangioendothelioma coexistent with pulmonary metastasis of thyroid cancer. (11518122)
2001
47
Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. (10787191)
2000
48
18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. (10404792)
1999
49
A case of follicular thyroid cancer with tracheal stenosis responded to external radiation therapy. (10378657)
1999
50
Infrequent CDKN2 mutation in human differentiated thyroid cancers. (8561866)
1996

Variations for Thyroid Cancer

About this section

Expression for genes affiliated with Thyroid Cancer

About this section
Search GEO for disease gene expression data for Thyroid Cancer.

Pathways for genes affiliated with Thyroid Cancer

About this section

Pathways related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50)    (show all 92)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
EGFR-dependent Endothelin signaling events36
9.9HRAS, EGF, NRAS
2
Show member pathways
9.9HRAS, EGF, NRAS
39.9HRAS, RET, PIK3CA
49.9EGF, HRAS, PIK3CA
5
Show member pathways
9.9HRAS, NRAS, BRAF
69.8PIK3CA, BRAF, HRAS
7
Show member pathways
9.7NRAS, PIK3CA, HRAS, EGF
8
Show member pathways
9.7NRAS, HRAS, BRAF, PIK3CA
99.7NRAS, HRAS, PIK3CA, BRAF
10
Show member pathways
9.7HRAS, EGF, NRAS, BRAF
11
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.7HRAS, CDKN1A, PTEN, PIK3CA
12
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells59
Oncostatin M Signaling Pathway36
9.6PPARG, NRAS, HRAS, BRAF
139.6PTEN, BRAF, CDKN1A, HRAS
149.5EGF, RASSF1, BRAF, PIK3CA
159.5PAX8, BRAF, PIK3CA, HRAS
16
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
9.5CDKN1A, HRAS, PIK3CA, PTEN, NRAS
17
Show member pathways
9.5BRAF, HRAS, RET, NRAS, PIK3CA
18
Show member pathways
9.5NRAS, PIK3CA, EGF, HRAS, BRAF
19
Show member pathways
Immune response BCR pathway59
Fc-epsilon receptor I signaling in mast cells36
9.5NRAS, PIK3CA, PTEN, BRAF, HRAS
20
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
9.5PTEN, HRAS, CDKN1A, EGF, PIK3CA
21
Show member pathways
9.4HRAS, EGF, NRAS, BRAF, PTEN
22
Show member pathways
9.4NRAS, HRAS, PIK3CA, CDKN1A, BRAF
239.4HRAS, BRAF, NRAS, CDKN1A, PIK3CA
24
Show member pathways
9.4NRAS, PIK3CA, PPARG, BRAF, HRAS
25
Show member pathways
IL-9 Signaling Pathway36
Development Thrombopoietin regulated cell processes59
IL-7 Signaling Pathway36
Immune response IL 9 signaling pathway59
9.4HRAS, PTEN, PIK3CA, BRAF, CDKN1A
269.3PTTG1, PIK3CA, NRAS, CDKN1A, HRAS
279.3PTEN, HRAS, EGF, CDKN1A, NRAS, PIK3CA
28
Show member pathways
9.3CDKN1A, PTEN, HRAS, EGF, NRAS, PIK3CA
29
Show member pathways
9.3PIK3CA, PTEN, NRAS, HRAS, CDKN1A, EGF
30
Show member pathways
9.3EGF, HRAS, CDKN1A, PIK3CA, PTEN, NRAS
31
Show member pathways
Development ERBB family signaling59
Development GDNF family signaling59
9.3NRAS, HRAS, RET, BRAF, PIK3CA, EGF
32
Show member pathways
Integrin-mediated cell adhesion36
Focal Adhesion36
9.2EGF, HRAS, NRAS, BRAF, PTEN, PIK3CA
33
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.2PIK3CA, BRAF, NRAS, EGF, HRAS, PTEN
349.2EGF, PIK3CA, PTTG1, PTEN, CDKN1A
359.2NRAS, RASSF1, CDKN1A, HRAS, PTEN, PIK3CA
369.2PIK3CA, CDKN1A, HRAS, BRAF, EGF, NRAS
37
Show member pathways
9.2PIK3CA, BRAF, NRAS, CDKN1A, HRAS, EGF
38
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.2PIK3CA, EGF, BRAF, NRAS, HRAS, CDKN1A
399.2EGF, CDKN1A, NRAS, BRAF, PTEN, HRAS
40
Show member pathways
9.2PIK3CA, HRAS, BRAF, NRAS, EGF, RASSF1
41
Show member pathways
9.2BRAF, PPARG, PTEN, NRAS, EGF, HRAS
429.1BRAF, HRAS, NRAS, RET, PAX8, PPARG
43
Show member pathways
Signal transduction PTEN pathway59
9.0PIK3CA, HRAS, EGF, CDKN1A, NRAS, BRAF
44
Show member pathways
9.0BRAF, HRAS, EGF, CDKN1A, NRAS, PTEN
45
Show member pathways
PLK2 and PLK4 events36
Polo-like kinase signaling events in the cell cycle36
9.0PTEN, PIK3CA, BRAF, NRAS, CDKN1A, HRAS
46
Show member pathways
Transcription Receptor mediated HIF regulation59
Development CNTF receptor signaling59
Class IB PI3K non-lipid kinase events36
ErbB2/ErbB3 signaling events36
Development Growth hormone signaling via PI3K AKT and MAPK cascades59
Translation Regulation activity of EIF259
Regulation of lipid metabolism Insulin signaling generic cascades59
Transcription PPAR Pathway59
Cell adhesion PLAU signaling59
Translation Regulation activity of EIF4F59
9.0PIK3CA, PPARG, PTEN, BRAF, NRAS, EGF
47
Show member pathways
Signaling Pathways in Glioblastoma36
8.8PTEN, NRAS, PIK3CA, EGF, CDKN1A, BRAF
488.7HRAS, PTEN, PIK3CA, BRAF, CALCA, NRAS
49
Show member pathways
8.2KISS1R, HRAS, EGF, PIK3CA, CDKN1A, PTEN
508.0RET, PPARG, HRAS, EGF, CDKN1A, RASSF1

Compounds for genes affiliated with Thyroid Cancer

About this section

Compounds related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50)    (show all 90)
idCompoundScoreTop Affiliating Genes
1panitumumab44 50 1112.1EGF, BRAF, PTEN
2phenylacetate4410.1HRAS, CDKN1A, PPARG
3mithramycin449.9CDKN1A, PPARG, CALCA
4iodine44 2410.8BRAF, TSHR, TG
5gefitinib44 50 1111.8CDKN1A, EGF, PIK3CA, PTEN
6crcs449.8PTEN, HRAS, RASSF1, BRAF, PIK3CA
7gemcitabine44 50 1111.8PTEN, CDKN1A, EGF, HRAS
8rosiglitazone28 44 50 24 1113.8PPARG, TSHR, CDKN1A, PIK3CA, PTEN
9imatinib44 50 1111.7CDKN1A, PIK3CA, PTEN, BRAF, RET
10phosphotyrosine449.7RET, PIK3CA, HRAS, PTEN, EGF
11lovastatin44 50 60 28 1113.7PTEN, CDKN1A, EGF, HRAS
12calcitriol44 60 24 1112.6EGF, CDKN1A, CALCA, PTEN, TG
13sodium iodide449.6TG, BRAF, PAX8, TSHR, RET, NKX2-1
14thyroxine44 2410.6TG, PAX8, CALCA, TSHR, PPARG
15iodide44 2410.6PIK3CA, TG, BRAF, PAX8, TSHR, NKX2-1
1612-o-tetradecanoylphorbol 13-acetate449.6HRAS, CDKN1A, TSHR, BRAF, RET, EGF
17phosphoinositide449.5BRAF, TSHR, EGF, HRAS, PIK3CA, PTEN
18paclitaxel44 50 1111.5CDKN1A, HRAS, BRAF, PTEN, PIK3CA, EGF
19methionine449.5HRAS, PTEN, TSHR, RET, RASSF1
20aspartate449.5TSHR, PTEN, BRAF, HRAS, TG, RET
21ribonucleic acid449.4TG, PTTG1, RET, PAX8, NKX2-1, TSHR
22pge2449.4PTEN, CALCA, PPARG, CDKN1A, EGF, HRAS
23adenylate449.4CALCA, EGF, TSHR, TG, PIK3CA, HRAS
24pd 98,059449.4HRAS, CDKN1A, BRAF, PTEN, PIK3CA, RET
25wortmannin449.4PIK3CA, EGF, PTEN, CDKN1A, RET, BRAF
26sodium44 2410.4PAX8, TSHR, NKX2-1, HRAS, TG, PIK3CA
27forskolin44 50 1111.4CALCA, TSHR, BRAF, EGF, PAX8, NKX2-1
28rapamycin449.3PIK3CA, EGF, CDKN1A, BRAF, PPARG, PTEN
29arginine449.3TSHR, RET, TG, BRAF, PIK3CA, HRAS
30thymidine44 2410.3HRAS, TSHR, TG, PTTG1, EGF, PIK3CA
31paraffin449.3PTEN, TG, BRAF, RET, CDKN1A, TSHR
32testosterone44 60 24 1112.3PIK3CA, CALCA, PTEN, EGF, RET, TG
33genistein44 28 60 1 24 1114.3EGF, CDKN1A, PTEN, PPARG, PIK3CA, TG
34progesterone44 28 60 24 1113.2CDKN1A, PTEN, HRAS, PIK3CA, BRAF, TSHR
35cyclic amp44 2410.2HRAS, NKX2-1, TSHR, CALCA, RET, EGF
36ly294002449.2RET, PIK3CA, HRAS, EGF, CDKN1A, PTEN
37cisplatin44 50 60 1112.2EGF, PIK3CA, PTEN, HRAS, BRAF, TG
38phosphatidylinositol449.1PIK3CA, PTTG1, PTEN, BRAF, TSHR, RET
39alanine449.0PPARG, KISS1R, RASSF1, RET, TSHR, BRAF
40h2o2449.0PIK3CA, PTEN, TG, CDKN1A, EGF, HRAS
41cysteine448.9TG, TSHR, PTTG1, PTEN, RET, EGF
42oligonucleotide448.7RASSF1, PTEN, BRAF, PAX8, TSHR, RET
43threonine448.5RET, PTEN, BRAF, PAX8, TSHR, HRAS
44agar448.5HRAS, CDKN1A, RASSF1, NRAS, RET, BRAF
45tyrosine448.4BRAF, TG, HRAS, PTEN, TSHR, RET
46retinoic acid44 249.4EGF, CDKN1A, RASSF1, NKX2-1, TSHR, PIK3CA
47calcium44 50 24 1111.4CALCA, KISS1R, PTEN, EGF, HRAS, PIK3CA
48serine448.3HRAS, BRAF, TG, CDKN1A, RASSF1, NKX2-1
49vegf448.2PIK3CA, PTTG1, HRAS, PTEN, TSHR, PPARG
50estrogen448.0PPARG, BRAF, HRAS, EGF, PIK3CA, PTTG1

GO Terms for genes affiliated with Thyroid Cancer

About this section

Cellular components related to Thyroid Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1plasma membraneGO:00058868.5PTEN, BRAF, TSHR, NRAS, RASSF1, KISS1R
2cytosolGO:00058298.1HRAS, NNMT, PPARG, PIK3CA, PTTG1, PTEN

Biological processes related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of Rac protein signal transductionGO:003502210.3NRAS, HRAS
2regulation of synaptic transmission, GABAergicGO:003222810.3NRAS, HRAS
3thyroid-stimulating hormone signaling pathwayGO:003819410.3TSHR, PAX8
4thyroid gland developmentGO:003087810.1NKX2-1, PAX8, TG
5MAPK cascadeGO:000016510.1NRAS, RET, HRAS
6response to arsenic-containing substanceGO:004668510.1CDKN1A, PTEN
7endothelial cell migrationGO:004354210.1PIK3CA, CALCA, PTEN
8positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic processGO:0200006010.0EGF, PTEN
9striated muscle cell differentiationGO:005114610.0HRAS, NRAS
10Ras protein signal transductionGO:000726510.0NRAS, HRAS, CDKN1A, RASSF1
11negative regulation of neuron apoptotic processGO:004352410.0HRAS, PIK3CA, BRAF, NRAS
12leukocyte migrationGO:00509009.9NRAS, PIK3CA, HRAS
13phosphatidylinositol-mediated signalingGO:00480159.9CDKN1A, PTEN, EGF, PIK3CA
14organ regenerationGO:00311009.8NNMT, PPARG, CDKN1A
15positive regulation of cell proliferationGO:00082849.8NRAS, TSHR, HRAS, PTEN, EGF
16activation of MAPKK activityGO:00001869.7BRAF, NRAS, KISS1R, EGF, HRAS
17negative regulation of cell proliferationGO:00082859.7CDKN1A, RNF139, PTEN, HRAS, KISS1R
18Fc-epsilon receptor signaling pathwayGO:00380959.6HRAS, EGF, CDKN1A, NRAS, PTEN, PIK3CA
19epidermal growth factor receptor signaling pathwayGO:00071739.6PTEN, HRAS, NRAS, PIK3CA, CDKN1A, EGF
20positive regulation of transcription, DNA-templatedGO:00458939.5EGF, PPARG, PAX8, RET, NKX2-1
21response to drugGO:00424939.5CDKN1A, NNMT, PPARG, RET, PTEN
22fibroblast growth factor receptor signaling pathwayGO:00085439.4EGF, NRAS, BRAF, PTEN, PIK3CA, HRAS
23innate immune responseGO:00450879.4NRAS, EGF, CDKN1A, PIK3CA, PPARG, HRAS
24neurotrophin TRK receptor signaling pathwayGO:00480119.4BRAF, PIK3CA, NRAS, PTEN, CDKN1A, EGF
25protein phosphorylationGO:00064689.2BRAF, CDKN1A, CALCA, RET

Molecular functions related to Thyroid Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1thyroid-stimulating hormone receptor activityGO:000499610.0TSHR, PAX8
2protein bindingGO:00055156.4HRAS, PPARG, PIK3CA, PTTG1, PTEN, BRAF

Sources for Thyroid Cancer

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet